Molecular Partners (ADR) (MOLN)
Develops DARPin cancer therapies, including Radio-DARPins and immune-cell engagers.
Something off on this page? Send us feedback.
Develops oncology-focused DARPin therapies through proprietary and partnered clinical programs. The pipeline combines Radio-DARPins with immune-cell engagers, while the company remains a clinical-stage developer without product revenue.
Develops DARPin therapeutics for oncology through proprietary and partnered programs. MP0712 is a DLL3-targeted, lead-212-labelled Radio-DARPin in a US Phase 1/2a study for small-cell lung cancer and other DLL3-expressing neuroendocrine cancers. MP0726 targets mesothelin, while the Radio-DARPin collaboration with Orano Med covers a broader program set.
Other programs include MP0533, a multispecific T-cell engager for AML and MDS/AML, and MP0317, a tumor-localized CD40 agonist for cholangiocarcinoma. Switch-Darpins are next-generation immune-cell engagers in development.
Domiciled in Schlieren, Switzerland, the company also reports an office in Concord, Massachusetts. Clinical execution, radiopharmaceutical partnerships, and continuing operating funding shape the business.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Jan 27, 2026 | H.C. Wainwright | Target | $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $83.6M · Total debt $3.7M · Total assets $93.2M · Shareholders' equity $72.1M
- Revenue
- $0
- Operating income
- −$17.0M
- Net income
- −$17.0M
Reported in CHF, converted at the latest exchange rate
No dividends on record.
| Institutions4 holders · as of Mar 31, 2026 | 9.57% | 3.59M ADS | |
| Strategic holders1 holder · as of Jul 17, 2025 | 5.72% | 2.14M ADS | |
| Otherremainder | 84.71% | 31.78M ADS |
37.51M ADS as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Suvretta Capital Management, LLCInstitution | 5.92% | 2.22M ADS | 13Fas of Mar 31, 2026 |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCStrategic | 5.72% | 2.14M | 13Gfiled Jul 17, 2025 ↗ |
BVF Inc/ILInstitution | 3.61% | 1.35M ADS | 13Fas of Mar 31, 2026 |
Smartharvest Portfolios, LLCInstitution | 0.04% | 15,543 ADS | 13Fas of Mar 31, 2026 |
Morgan StanleyInstitution | 0.00% | 367 ADS | 13Fas of Mar 31, 2026 |
| See all 6 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Amgen
Approved DLL3 therapy in extensive-stage small-cell lung cancer
- Zai Lab (ADR)
Late-stage DLL3 ADC in SCLC and neuroendocrine carcinomas
- Legend Biotech (ADR)
DLL3 CAR-T in Phase 1 for SCLC and neuroendocrine carcinoma
- MacroGenics
CD123×CD3 engager in ongoing AML and MDS dose escalation
- Context Therapeutics
Mesothelin×CD3 T-cell engager in Phase 1 solid-tumor trial
- Genmab (ADR)
CD40×4-1BB agonist in Phase 1/2 solid-tumor trials
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Molecular Partners (ADR) | $4.24 | +0.65% | $152.7M | — | — | — | — |
| Amgen | $442.21 | −0.14% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Zai Lab (ADR) | $26.88 | +1.47% | $2.99B | — | — | 6.6 | −3.3% |
| Legend Biotech (ADR) | $21.99 | +0.41% | $4.05B | — | 46.9 | 3.2 | +51.4% |
| MacroGenics | $4.36 | +1.02% | $274.6M | — | — | 1.6 | +47.6% |
| Context Therapeutics | $0.3517 | −4.01% | $33.3M | — | — | — | — |
| Genmab (ADR) | $34.37 | +0.45% | $21.01B | 27.0 | 26.6 | 2.1 | +24.9% |
| Median | 27.2 | 26.6 | 3.2 | +24.9% |